Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

December 16, 2014

Targeting PARPs with Novel Drugs: Back to the Laboratory?

Exploiting synthetic lethality for cancer therapy.

Targeting PARPs with Novel Drugs: Back to the Laboratory?

The presence of a mutation in cancer cells creates opportunities to selectively kill those tumor cells by mimicking the effect of a second genetic mutation with targeted therapy, as in the case of PARP inhibitors. [Royalty Stock Photo/Shutterstock]

Drug candidate inhibitors of poly (ADP-ribose) polymerase 1 (PARP1) have generated interest among pharma companies and investors But the enthusiasm waned when the PARP inhibitor iniparib, deemed “the next big thing” in cancer drug development, failed a Phase III clinical trial...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.

Related content